Literature DB >> 30942453

[Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.

Qungen Xiao1, Minhai Dong1, Fangling Cheng1, Feng Mao1, Weifeng Zong1, Kang Wu1, Heping Wang1, Ruifan Xie1, Baofeng Wang1, Ting Lei1, Dongsheng Guo1.   

Abstract

Following the publication of this article, the authors have realized that the name of the second author was misspelt: "Minghai Dong" should have appeared as "Minhai Dong". The correct information for the authors on this paper is presented above. The authors regret that this error made it into print, andapologize to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 53: 1069‑1082, 2018; DOI: 10.3892/ijo.2018.4482].

Entities:  

Year:  2019        PMID: 30942453      PMCID: PMC6521924          DOI: 10.3892/ijo.2019.4769

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


Int J Oncol 53: 1069-1082, 2018; DOI: 10.3892/ijo.2018.4482 Following the publication of this article, the authors have realized that the name of the second author was misspelt: “Minghai Dong” should have appeared as “Minhai Dong”. The correct information for the authors on this paper is presented above. The authors regret that this error made it into print, and apologize to the readership for any inconvenience caused.
  1 in total

Review 1.  Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Authors:  Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.